Not available
Quote | Cellectis S.A. (NASDAQ:CLLS)
Last: | $2.30 |
---|---|
Change Percent: | -8.29% |
Open: | $2.22 |
Close: | $2.30 |
High: | $2.43 |
Low: | $2.157 |
Volume: | 400,310 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Cellectis S.A. (NASDAQ:CLLS)
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
Message Board Posts | Cellectis S.A. (NASDAQ:CLLS)
Subject | By | Source | When |
---|---|---|---|
https://ih.advfn.com/stock-market/NASDAQ/cellectis-$CLLS/stock-news/83912184/cell | Frankestin | investorshub | 01/10/2023 5:27:59 PM |
Cellectis Announces Positive Preliminary Clinical Data for UCART22 | Frankestin | investorshub | 12/14/2022 8:39:18 AM |
will there be something interesting? | Frankestin | investorshub | 11/01/2022 10:53:45 AM |
also interesting here! | Frankestin | investorshub | 06/01/2022 5:10:36 PM |
News: $CLLS Cellectis and Lonza Enter cGMP Manufacturing | whytestocks | investorshub | 10/01/2019 8:40:21 PM |
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...